Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darzalex Faspro Before Standard Desensitization and AlloBMT in High-risk Patients
NCT06398457Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in graft failure after allogeneic hematopoietic cell transplantation, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Percentage of patients with reduced DSA levels at 2 years and Proportion of patients with grade 3 or higher toxicities at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
graft failure after allogeneic hematopoietic cell transplantation
Beyond the preview
Go deeper on NCT06398457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398457.